LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Home・Akciju saraksts・Erasca Inc

Erasca Inc

Slēgts

12.42 8.19

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

11.48

Max

12.77

Galvenie mērījumi
By Trading Economics
Ienākumi	-154M -183M
EPS	-0.6
Darbinieki	103
EBITDA	-5.3M -37M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+76.26% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 10. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	249M 3.5B
Iepriekšējā atvēršanas cena	4.23
Iepriekšējā slēgšanas cena	12.42

Erasca Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 26. maijs 16:52 UTC

Galvenie ziņu notikumi

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

2026. g. 26. maijs 23:57 UTC

Peļņas

Sociedad Quimica 1Q Rev $1.76B >SQM

2026. g. 26. maijs 23:57 UTC

Peļņas

Sociedad Quimica 1Q EPS $1.28 >SQM

2026. g. 26. maijs 23:48 UTC

Tirgus saruna

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

2026. g. 26. maijs 21:54 UTC

Peļņas

Webco Industries 3Q EPS $11.61 >WEBC

2026. g. 26. maijs 21:54 UTC

Peļņas

Webco Industries 3Q Sales $179.6M >WEBC

2026. g. 26. maijs 21:48 UTC

Tirgus saruna

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

2026. g. 26. maijs 21:00 UTC

Tirgus saruna

ESG Roundup: Market Talk

2026. g. 26. maijs 20:58 UTC

Iegādes, apvienošanās, pārņemšana

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

2026. g. 26. maijs 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 26. maijs 20:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 26. maijs 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 26. maijs 19:22 UTC

Tirgus saruna

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

2026. g. 26. maijs 19:17 UTC

Tirgus saruna

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

2026. g. 26. maijs 18:56 UTC

Tirgus saruna

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

2026. g. 26. maijs 18:03 UTC

Tirgus saruna

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

2026. g. 26. maijs 17:42 UTC

Tirgus saruna

Grains Await Fresh Trading Catalyst -- Market Talk

2026. g. 26. maijs 17:33 UTC

Tirgus saruna

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

2026. g. 26. maijs 17:21 UTC

Tirgus saruna

Canada Faces a Labor Market Squeeze -- Market Talk

2026. g. 26. maijs 16:52 UTC

Tirgus saruna

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

2026. g. 26. maijs 16:43 UTC

Tirgus saruna

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

2026. g. 26. maijs 16:24 UTC

Tirgus saruna

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

2026. g. 26. maijs 16:21 UTC

Tirgus saruna

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

2026. g. 26. maijs 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 26. maijs 16:20 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2026. g. 26. maijs 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 26. maijs 16:20 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Auto & Transport Roundup: Market Talk

2026. g. 26. maijs 16:16 UTC

Tirgus saruna

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

2026. g. 26. maijs 16:01 UTC

Tirgus saruna

Bitcoin Lower as Stress Builds for Holders -- Market Talk

2026. g. 26. maijs 15:21 UTC

Tirgus saruna

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Salīdzinājums

Cenas izmaiņa

Erasca Inc Prognoze

Cenas mērķis

By TipRanks

76.26% augšup

Prognoze 12 mēnešiem

Vidējais 20.27 USD 76.26%

Augstākais 30 USD

Zemākais 9 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Erasca Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

11 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 11 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Erasca Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.